Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1428 studies found for:    Kennedy's Disease
Show Display Options
Rank Status Study
21 Recruiting Study of Hepatic Function in Patients With Spinal and Bulbar Muscular Atrophy
Conditions: Liver;   Motor Neuron Disease
Intervention:
22 Active, not recruiting A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC
Condition: Prostate Cancer
Interventions: Drug: Galeterone;   Drug: Enzalutamide
23 Terminated GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer
Conditions: Estrogen Receptor Negative Breast Cancer;   Human Epidermal Growth Factor 2 Negative Carcinoma of Breast;   Triple Negative Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: cisplatin;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Procedure: dynamic contrast-enhanced MRI, diffusion-weighted MRI & chemical exchange saturation transfer MRI;   Drug: GDC -0941
24 Not yet recruiting Androgen Receptor Antagonist ARN-509, Abiraterone Acetate, Prednisone, Degarelix, and Indomethacin in Treating Patients With Localized Prostate Cancer Before Surgery
Conditions: Stage III Prostate Adenocarcinoma;   Stage III Prostate Cancer;   Stage IV Prostate Adenocarcinoma;   Stage IV Prostate Cancer
Interventions: Drug: Abiraterone Acetate;   Drug: Androgen Receptor Antagonist ARN-509;   Drug: Degarelix;   Drug: Indomethacin;   Other: Laboratory Biomarker Analysis;   Drug: Prednisone
25 Suspended A Phase 1a/1b Study to Evaluate the Safety of EZN-4176, in Adult Patients With Castration-Resistant Prostate Cancer
Condition: Prostatic Neoplasm
Intervention: Drug: EZN-4176
26 Not yet recruiting ARN-509 in Treating Patients With Prostate Cancer Who Are in Active Surveillance
Condition: Stage II Prostate Adenocarcinoma
Interventions: Drug: Androgen Receptor Antagonist ARN-509;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
27 Recruiting Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers
Condition: Salivary Cancer
Intervention: Drug: enzalutamide
28 Recruiting Bicalutamide as A Treatment in AR-positive Metastatic Triple-Negative Breast Cancer (mTNBC) Patients
Condition: Breast Cancer
Intervention: Drug: Bicalutamide
29 Withdrawn STA-9090 in Castration-Resistant Prostate Cancer With Assessment of Androgen Receptor Pathway Signaling
Condition: Adenocarcinoma of the Prostate
Interventions: Drug: STA9090;   Drug: STA9090 with Dutasteride
30 Active, not recruiting The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: ARN-509;   Drug: LHRH Agonist
31 Recruiting A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD) +/-GMCSF
Condition: Prostate Cancer
Interventions: Biological: pTVG-AR;   Biological: gm-csf
32 Recruiting Phase IIB Neoadjuvant Enzalutamide (ZT) Plus Taxol for Androgen Receptor (AR)-Positive Triple-Negative Breast Cancer (AR+ TNBC)
Condition: Breast Cancer
Interventions: Drug: Enzalutamide;   Drug: Paclitaxel
33 Withdrawn Oral Microencapsulated Diindolylmethane in Treating Patients With Stage II-III Triple Negative, Androgen Receptor Positive Breast Cancer Who Have Undergone Chemotherapy and Surgery
Condition: Breast Cancer Female
Interventions: Drug: oral microencapsulated diindolylmethane;   Other: laboratory biomarker analysis
34 Recruiting Androgen Deprivation Therapy in Advanced Salivary Gland Cancer
Condition: Salivary Gland Cancer
Interventions: Drug: bicalutamide + triptorelin;   Drug: Cisplatin + Doxorubicin;   Drug: Carboplatin + Paclitaxel
35 Completed Effect of Functional Exercise in Patients With Spinal Bulbar Muscular Atrophy
Condition: Motor Neuron Disease
Interventions: Behavioral: A functional exercise program;   Behavioral: A stretching exercise program
36 Completed Gene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone Therapy
Condition: Prostate Cancer
Intervention: Other: mutation analysis
37 Active, not recruiting Sodium Fluoride (NaF) Positron Emission Tomography/Computed Tomography (PET/CT) in Patients With Metastatic Castrate-resistant Prostate Cancer (CRPC) With Microtubule Directed Chemo or AR-directed Therapy
Condition: Prostate Cancer
Intervention: Procedure: Sodium Fluoride (NaF) Positron Emission Tomography/Computed Tomography (PET/CT) imaging
38 Recruiting Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer
Conditions: Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor Negative;   Recurrent Breast Carcinoma;   Stage IV Breast Cancer;   Triple-Negative Breast Carcinoma
Interventions: Drug: Galunisertib;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel
39 Recruiting Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic Study of GSK2881078 and Study to Evaluate the Effect of CYP3A4 Inhibition on PK of GSK2881078
Condition: Cachexia
Interventions: Drug: GSK2881078;   Drug: Placebo;   Drug: Itraconazole
40 Completed AR and ER Imaging in Metastatic Breast Cancer
Condition: Metastatic Breast Cancer
Interventions: Other: FDHT-PET scan;   Other: FES-PET scan;   Other: CT-scan;   Other: Bone scintigraphy;   Other: Tumor biopsy

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.